Department of Radiation Oncology, New York University Langone Medical Center, NY 10016, USA.
Cancer Chemother Pharmacol. 2012 Sep;70(3):353-63. doi: 10.1007/s00280-012-1926-7. Epub 2012 Jul 24.
Central to the process of brain tumor development is angiogenesis, which involves a host of molecules and receptors. In recent years, antiangiogenic therapies have been developed and tested for their effectiveness against these tumors. Among them are inhibitors against vascular endothelial growth factor and its receptors, as well as inhibitors targeting the platelet-derived growth factor family, integrins, and histone deacetylase. While many have been shown to be effective with limited toxicity, some tumors are able to adopt escape mechanisms. Further research is needed in the development of effective multi-targeted agents to reduce these effects.
脑肿瘤发展的核心过程是血管生成，涉及许多分子和受体。近年来，已经开发出抗血管生成疗法，并对其针对这些肿瘤的有效性进行了测试。其中包括针对血管内皮生长因子及其受体的抑制剂，以及针对血小板衍生生长因子家族、整合素和组蛋白去乙酰化酶的抑制剂。虽然许多抑制剂已被证明具有有限的毒性，但有些肿瘤能够采用逃避机制。需要进一步研究开发有效的多靶点药物来减少这些影响。
